Robert Ellis

Dr. Robert Ellis


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2016 in Nephrology
Verified
Journal Article
Closed access
PDF file
RERobert Ellis
Robert Ellis
DSDavid M Small
David M Small
David VeseyDavid Vesey
David Vesey
DJDavid W Johnson
David W Johnson
RFRoss Francis
Ross Francis
CMChristudas Morais
Christudas Morais

22 April 2018 in Toxicologic Pathology
Verified
Journal Article
Closed access
RERobert Ellis
Robert Ellis
DSDavid M. Small
David M. Small
KNKeng Lim Ng
Keng Lim Ng
David VeseyDavid Vesey
David Vesey
LVLuis Vitetta
Luis Vitetta
CMChristudas Morais
Christudas Morais
Indoxyl sulfate (IS) is a protein-bound uremic toxin that accumulates in patients with declining kidney function. Although generally thought of as a consequence of declining kidney function, emerging evidence demonstrates direct cytotoxic role of IS on endothelial cells and cardiomyocytes, largely through the expression of pro-inflammatory and pro-fibrotic factors. The direct toxicity of IS on human kidney proximal tubular epithelial cells (PTECs) remains a matter of debate. The current study explored the effect of IS on primary cultures of human PTECs and HK-2, an immortalized human PTEC line. Pathologically relevant concentrations of IS induced apoptosis and increased the expression of the proapoptotic molecule Bax in both cell types. IS impaired mitochondrial metabolic activity and induced cellular hypertrophy. Furthermore, statistically significant upregulation of pro-fibrotic (transforming growth factor-β, fibronectin) and pro-inflammatory molecules (interleukin-6, interleukin-8, and tumor necrosis factor-α) in response to IS was observed. Albumin had no influence on the toxicity of IS. The results of this study suggest that IS directly induced a pro-inflammatory and pro-fibrotic phenotype in proximal tubular cells. In light of the associated apoptosis, hypertrophy, and metabolic dysfunction, this study demonstrates that IS may play a role in the progression of chronic kidney disease.

8 October 2018 in Journal of Kidney Cancer
Verified
Journal Article
Open access
PDF file
SVSharon J. Del Vecchio
Sharon J. Del Vecchio
RERobert Ellis
Robert Ellis
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.

5 June 2018 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
RERobert Ellis
Robert Ellis
SVSharon J. Del Vecchio
Sharon J. Del Vecchio
BKBenjamin Kalma
Benjamin Kalma
KNKeng Lim Ng
Keng Lim Ng
CMChristudas Morais
Christudas Morais
SWSimon T. Wood
Simon T. Wood

15 December 2022 in Medical Journal of Australia
Verified
Journal Article
Open access
RERobert Ellis
Robert Ellis
CMCameron Moffatt
Cameron Moffatt
LALuke T Aaron
Luke T Aaron
GBGreta Beaverson
Greta Beaverson
KCKhin Chaw
Khin Chaw
SASatyamurthy Anuradha
Satyamurthy Anuradha
To identify characteristics associated with the hospitalisation and death of people with COVID‐19 living in residential aged care facilities (RACFs). Retrospective cohort study. All confirmed (polymerase chain reaction testing) or probable SARS‐CoV‐2 infections (rapid antigen tests) in residents of the 86 RACFs in the Metro South Hospital and Health Service area (southeast Queensland), 13 December 2021 – 24 January 2022. Hospitalisation within 14 days or death within 28 days of COVID‐19 diagnosis. Of 1071 RACF residents with COVID‐19, 151 were hospitalised within 14 days and 126 died within 28 days of diagnosis. Likelihood of death increased with age (per five years: adjusted odds ratio [aOR], 1.38; 95% confidence interval [CI], 1.21–1.57), but not that of hospitalisation. Men were more likely to be hospitalised (aOR, 1.7; 95% CI, 1.2–2.4) or die (aOR, 2.5; 95% CI, 1.7–3.6) than women. The likelihood of hospitalisation was greater for those with dementia (aOR, 1.9; 95% CI, 1.2–3.0), heart failure (aOR, 1.7; 95% CI, 1.1–2.7), chronic kidney disease (aOR, 1.7; 95% CI, 1.1–2.5), or asthma (aOR, 2.2; 95% CI, 1.2–3.8). The likelihood of death was greater for residents with dementia (aOR, 2.2; 95% CI, 1.3–3.7), diabetes mellitus (aOR, 1.9; 95% CI, 1.3–3.0), heart failure (aOR, 2.0; 95% CI, 1.1–3.3), or chronic lung disease (aOR, 1.7; 95% CI, 1.1–2.7). The likelihood of hospitalisation and death were each higher for residents who had received two or fewer vaccine doses than for those who had received three doses. Most characteristics that influenced the likelihood of hospitalisation or death of RACF residents with COVID‐19 were non‐modifiable factors linked with frailty and general health status. Having received three COVID‐19 vaccine doses was associated with much lower likelihood of hospitalisation or death.

1 April 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
RERobert Ellis
Robert Ellis
SVSharon J. Del Vecchio
Sharon J. Del Vecchio
KGKevin M.J. Gallagher
Kevin M.J. Gallagher
DADanielle N. Aliano
Danielle N. Aliano
NBNeil Barber
Neil Barber
SJSusan J. Jordan
Susan J. Jordan
Significance Statement: Patients undergoing surgical management of kidney tumors are at increased risk of developing CKD. However, it is often difficult to identify patients at higher risk of clinically significant CKD before surgery, and there is a lack of validated tools to assist clinicians in this process. The authors developed and validated a simple scoring system that accurately and reproducibly stratifies risk of developing clinically significant CKD after nephrectomy on the basis of readily available parameters. This system provides an evidence-based quantitative tool for clinicians to balance the risk of CKD against other considerations when planning management of kidney tumors, and it will facilitate earlier identification of patients with a higher risk of developing clinically significant CKD, potentially leading to earlier intervention. Background: Clinically significant CKD following surgery for kidney cancer is associated with increased morbidity and mortality, but identifying patients at increased CKD risk remains difficult. Simple methods to stratify risk of clinically significant CKD after nephrectomy are needed. Methods: To develop a tool for stratifying patients’ risk of CKD arising after surgery for kidney cancer, we tested models in a population-based cohort of 699 patients with kidney cancer in Queensland, Australia (2012–2013). We validated these models in a population-based cohort of 423 patients from Victoria, Australia, and in patient cohorts from single centers in Queensland, Scotland, and England. Eligible patients had two functioning kidneys and a preoperative eGFR ≥60 ml/min per 1.73 m2. The main outcome was incident eGFR <45 ml/min per 1.73 m2 at 12 months postnephrectomy. We used prespecified predictors—age ≥65 years old, diabetes mellitus, preoperative eGFR, and nephrectomy type (partial/radical)—to fit logistic regression models and grouped patients according to degree of risk of clinically significant CKD (negligible, low, moderate, or high risk). Results: Absolute risks of stage 3b or higher CKD were <2%, 3% to 14%, 21% to 26%, and 46% to 69% across the four strata of negligible, low, moderate, and high risk, respectively. The negative predictive value of the negligible risk category was 98.9% for clinically significant CKD. The c statistic for this score ranged from 0.84 to 0.88 across derivation and validation cohorts. Conclusions: Our simple scoring system can reproducibly stratify postnephrectomy CKD risk on the basis of readily available parameters. This clinical tool’s quantitative assessment of CKD risk may be weighed against other considerations when planning management of kidney tumors and help inform shared decision making between clinicians and patients.